Framework agreement for the purchase of tests for measuring the concentrations of and antibodies directed against the drugs Adalimumab, Infliximab and Rituximab in human serum.

The purpose of the procurement is to enter into a framework agreement for the purchase of tests for measuring the concentration of and antibodies directed against the drugs Adalimumab, Infliskimab and Rituximab in human serum in patients with autoimmune inflammatory diseases (such as arthritis, Chron's disease, ulcerative colitis, psoriasis and multiple sclerosis (MS)).

The analyses are part of disease monitoring, where drug concentrations are monitored and the formation of unwanted antibodies (immunogenicity) is identified, which can lead to loss of effect and increase the risk of infusion reactions.